3,5-二乙酰氨基-2,4,6-三碘苯甲酸乙酯 | 2168-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二乙酰氨基-2,4,6-三碘苯甲酸乙酯
• 英文名称: 3,5-Bis-acetylamino-2,4,6-triiodo-benzoic acid ethyl ester
• 英文别名: ethyl diatrizoate；ethyl-3,5-diacetamido-2,4,6-triiodobenzoate；ethyl-3,5-bisacetoamido-2,4,6-triiodobenzoate；ethyl 3,5-diacetoamido-2,4,6-triiodobenzoate；ethyl-3,5-diacetoamido-2,4,6-triiodobenzoate；ethyl-3,5-diacetoamido-2,4-6-triiodobenzoate；ethyl 3,5-diacetamido-2,4,6-triiodobenzoate
• CAS: 2168-75-4
• 化学式: C₁₃H₁₃I₃N₂O₄
• 分子量: 641.971
• InChiKey: OBISGMNJKBVZBT-UHFFFAOYSA-N

物化性质

• 熔点：
  258-266 °C
• 沸点：
  611.6±55.0 °C(Predicted)
• 密度：
  2.324±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  84.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  3,5-二乙酰氨基-2,4,6-三碘苯甲酸乙酯 在 sodium hydroxide 作用下， 以 水 为溶剂， 以87.47 %的产率得到泛影酸
  参考文献：
  名称：

  CN114478295

  摘要：

  公开号：
• 作为产物：
  描述：

  泛影酸 、 碘乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 以91%的产率得到3,5-二乙酰氨基-2,4,6-三碘苯甲酸乙酯
  参考文献：
  名称：

  Embolus therapy using insoluble microparticles or vesicles containing contrast agents

  摘要：

  本发明提供了一种栓塞疗法的方法，包括将包含颗粒的组合物给药到人体或非人类动物受试者的灌注组织区域的血管中，所述颗粒的大小或制剂被选择以在所述受试者的目标部位产生栓塞，其特征在于，所述颗粒使用的是固态水不溶性的非放射性诊断有效化合物颗粒或封装非放射性诊断有效化合物的囊泡或其溶液，并且栓塞位置是通过诊断成像技术检测的。

  公开号：

  US20050265923A1

文献信息

• Composition of and method for preparing stable particles in a frozen aqueous matrix
  申请人：——

  公开号：US20030077329A1

  公开（公告）日：2003-04-24

  The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.

  本发明揭示了一种稳定的悬浮液组合物，其包含一种难溶于水的药物或化妆品，以药物或化妆品的颗粒形式悬浮于冻结水基体中，并揭示了其制备方法。该组合物稳定性长时间，优选为六个月或更长时间，适用于静脉、口服或非口服途径，例如肺部（吸入）、眼科或局部给药。
• COMPOSITION OF AND METHOD FOR PREPARING STABLE PARTICLES IN A FROZEN AQUEOUS MATRIX
  申请人：Kipp E. James

  公开号：US20060222710A1

  公开（公告）日：2006-10-05

  The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.

  本发明揭示了一种稳定的悬浮液组合物，该组合物以制药剂或化妆品的颗粒形式悬浮于冻结的水基基质中，并提供了其制备方法。该组合物稳定性能长时间保持，最好为六个月或更长时间，并适用于肠道内、口服或非口服途径，如肺部（吸入）、眼科或局部给药。
• (Polyalkoxy)sulfonate surface modifiers
  申请人：Kipp E. James

  公开号：US20060141048A1

  公开（公告）日：2006-06-29

  The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised of a non-polar polyether covalently linked to an anionic sulfonate group. The compounds have an amphipathic quality and preferably, are surface active. Such compounds are preferably useful as surface-active agents to coat and stabilize dispersions of particles in a continuous liquid medium. These surface-active agents may be applied in the stabilization of suspensions, emulsions, or liposome formulations intended for pharmaceutical, medical, cosmetic, or agricultural use. The particles that can be prepared by a variety of methods and will preferably comprise a pharmaceutical agent. Pharmaceutical compositions of the present invention can be used to treat a myriad of conditions and can be administered by many routes, including intravenous, intramuscular, subcutaneous, intrathecal, subdural, intracameral, intracerebral, intralesional, topical, oral, buccal, rectal, transcutaneous, pulmonary, and nasal.

  本发明涉及新型化合物、制造方法和使用方法。本发明还涉及具有本发明化合物中的一个或多个与其表面相关联的固体药物/活性剂颗粒。本发明化合物由非极性聚醚共价连接到阴离子磺酸基团上。该化合物具有两性性质，最好是表面活性。这样的化合物最好用作表面活性剂，用于包覆和稳定分散在连续液体介质中的颗粒。这些表面活性剂可用于稳定制药、医疗、化妆品或农业用途的悬浮液、乳液或脂质体制剂。可通过各种方法制备颗粒，颗粒最好包含一种药物。本发明的制药组合物可用于治疗多种疾病，并可通过许多途径给药，包括静脉、肌肉注射、皮下注射、蛛网膜下腔、硬膜外、眼前房、颅内、病变部位内、局部、口服、颊粘膜、直肠、经皮、肺和鼻腔。
• X-ray contrast compositions useful in medical imaging
  申请人：NanoSystems L.L.C.

  公开号：EP0498482A2

  公开（公告）日：1992-08-12

  An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, and a pharmaceutically acceptable carrier therefor is useful in x-ray diagnostic medical imaging methods. The agents can be delivered to a specific tissue or fluid site, for example, the blood pool, liver, spleen, kidney or lymph nodes. In one embodiment involving intravenous administration, preferred compositions provide effective imaging of the blood pool for remarkably long times.

  一种 X 射线造影剂组合物，其颗粒主要由一种非放射性结晶有机 X 射线造影剂组成，该造影剂表面吸附有表面改性剂，其吸附量足以保持有效平均粒径小于 400 纳米，该组合物还包括一种药学上可接受的载体，可用于 X 射线诊断医学成像方法。这些制剂可被输送到特定的组织或液体部位，例如血液池、肝脏、脾脏、肾脏或淋巴结。在一个涉及静脉给药的实施方案中，优选的组合物可在相当长的时间内对血液池进行有效成像。
• Surface modified drug nanoparticles
  申请人：NanoSystems L.L.C.

  公开号：EP0499299A2

  公开（公告）日：1992-08-19

  Dispersible particles consisting essentially of a crystalline drug substance having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm, methods for the preparation of such particles and dispersions containing the particles. Pharmaceutical compositions containing the particles exhibit unexpected bioavailability and are useful in methods of treating mammals.

  主要由结晶药物物质组成的可分散微粒，其表面吸附有表面改性剂，其吸附量足以使有效平均粒径小于约 400 nm。含有这种微粒的药物组合物具有意想不到的生物利用度，可用于治疗哺乳动物。